{"success":true,"data":{"pressRelease":{"id":"59925","rtpr_id":"nGNX999tjN","ticker":"ARTL","exchange":"NASDAQ","all_tickers":["ARTL"],"title":"Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success","author":"Globe Newswire","published_at":"2026-06-10T11:38:00.095Z","article_body":"SOLANA BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences,\nInc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage\npharmaceutical company focused on modulating lipid-signaling pathways to\ndevelop treatments for people living with cancer, pain, dermatological, or\nneurological conditions, announces that Myles Osborn, Lead Medicinal Chemist\nat Artelo, is delivering an oral presentation today highlighting encouraging\nmetabolite identification and profiling data from the Company's lead FABP\ninhibitor candidate, ART26.12, during the 7th RSC-BMCS/DMDG New Perspectives\nin DMPK and Medicinal Chemistry Conference, held at the Burlington House in\nLondon.\n\nThe presentation features results from metabolite identification studies\nconducted using plasma samples obtained from healthy volunteers enrolled in\nthe recently completed Single Ascending Dose (SAD) clinical study of ART26.12.\nSince drug metabolism and pharmacokinetic properties are critical factors\ncontributing to successful clinical development, early characterization of\nART26.12's metabolite profile provides valuable insight that may help\nstreamline future development activities and reduce program risk.\n\nKey findings include:\n* Only three metabolites were detected from the plasma of healthy volunteers\nadministered a single 900 mg oral dose of ART26.12.\n* Total metabolite exposure represented approximately 7% of overall\ndrug-related exposure, indicating that the vast majority of circulating\ndrug-related material was the parent compound, ART26.12.\n* The primary metabolite detected, accounting for approximately 5% of total\ndrug-related exposure, was successfully identified and shown to have\nbiological activity comparable to ART26.12.\n* All three metabolites identified in humans were previously detected in the\nnonclinical species used in the ART26.12 toxicology program and are of no\nsafety concern.\n* Collectively, these findings suggest a low-risk metabolite profile, which\nmay simplify future development activities and further support advancement of\nART26.12 through clinical development.\n\"Understanding the metabolic fate of ART26.12 early in clinical development\nhas been an important objective for our team,\" said Myles Osborn, Lead\nMedicinal Chemist at Artelo. \"It was important for us to quantify and gain\nearly structural and biological knowledge of the metabolites, which we believe\nwill de-risk and significantly simplify future development of ART26.12.\"\n\n\"Up to 40% of drug development failures have historically been attributed to\nchallenges associated with pharmacokinetics and ADME (i.e. Absorption,\nDistribution, Metabolism and Excretion) properties,\" said Andrew Yates, Ph.D.,\nChief Scientific Officer of Artelo. \"These data further strengthen our\nconfidence in ART26.12, adding to the positive dose-proportional\npharmacokinetics, safety and tolerability observations we have already\nreported from our SAD study ART26.12-100. Importantly, the absence of\nhuman-specific metabolites and the low overall metabolite burden with ART26.12\nis expected to reduce future development complexity, timelines, and cost.\"\n\nIn summary, the ART26.12 metabolite profile characterized from healthy\nvolunteers is comprised of low plasma levels of only three metabolites\npreviously observed and qualified in its toxicology program. These results\nsuggest that these low level metabolites do not present a safety concern and,\ntogether with the remarkable safety profile observed in the SAD study, support\nthe continued development of ART26.12 for the treatment of pain.\n\nAbout Artelo Biosciences   \n\nArtelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated\nto the development and commercialization of proprietary therapeutics that\nmodulate lipid-signaling pathways, with a diversified pipeline addressing\nsignificant unmet needs in anorexia, cancer, anxiety, dermatologic conditions,\npain, and inflammation. Led by an experienced executive team collaborating\nwith world-class researchers and technology partners, Artelo applies rigorous\nscientific, regulatory, commercial, and treasury management practices,\nincluding digital assets, to maximize stakeholder value. More information is\navailable at www.artelobio.com and X: @ArteloBio.\n\nAbout ART26.12\n\nART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, is\nunder development as a novel, peripherally acting, non-opioid, non-steroidal\nanalgesic, initially for the treatment of chemotherapy-induced peripheral\nneuropathy (CIPN). Human studies with ART26.12 have demonstrated a favorable\nsafety profile with no serious adverse events, as well as predictable, linear\npharmacokinetics and dosing flexibility in both fed and fasted states. Fatty\nAcid Binding Proteins (FABPs) are a family of intracellular proteins that\nchaperone lipids important to normal cellular function. In addition to\nART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs\nhas shown therapeutic promise for the treatment of certain cancers,\nneuropathic and nociceptive pain, psoriasis, and anxiety disorders.\n\nForward-Looking Statements\n\nThis press release contains certain forward-looking statements within the\nmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the\nSecurities Exchange Act of 1934 and Private Securities Litigation Reform Act,\nas amended, including those relating to the Company’s product development,\nclinical and regulatory timelines, market opportunity, competitive position,\npossible or assumed future results of operations, business strategies,\npotential growth opportunities and other statements that are predictive in\nnature. These forward-looking statements are based on current expectations,\nestimates, forecasts and projections about the industry and markets in which\nwe operate and management’s current beliefs and assumptions. These\nstatements may be identified by the use of forward-looking expressions,\nincluding, but not limited to, “expect,” “anticipate,” “intend,”\n“plan,” “believe,” “estimate,” “potential,” “predict,”\n“project,” “should,” “would” and similar expressions and the\nnegatives of those terms. These statements relate to future events or our\nfinancial performance and involve known and unknown risks, uncertainties, and\nother factors which may cause actual results, performance or achievements to\nbe materially different from any future results, performance or achievements\nexpressed or implied by the forward-looking statements. Such factors include\nthose set forth in the Company’s filings with the Securities and Exchange\nCommission, including our ability to raise additional capital in the future.\nProspective investors are cautioned not to place undue reliance on such\nforward-looking statements, which speak only as of the date of this press\nrelease. The Company undertakes no obligation to publicly update any\nforward-looking statement, whether as a result of new information, future\nevents or otherwise, except to the extent required by applicable securities\nlaws.\n\nInvestor Relations Contact: \nCrescendo Communications, LLC \nTel: 212-671-1020 \nEmail: ARTL@crescendo-ir.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/460502d7-b0d3-43d8-a15a-5b2bb963bbbb)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX999tjN","title":"Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success","author":"Globe Newswire","ticker":"ARTL","created":"2026-06-10T11:38:00.095Z","tickers":["ARTL"],"exchange":"NASDAQ","article_body":"SOLANA BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences,\nInc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage\npharmaceutical company focused on modulating lipid-signaling pathways to\ndevelop treatments for people living with cancer, pain, dermatological, or\nneurological conditions, announces that Myles Osborn, Lead Medicinal Chemist\nat Artelo, is delivering an oral presentation today highlighting encouraging\nmetabolite identification and profiling data from the Company's lead FABP\ninhibitor candidate, ART26.12, during the 7th RSC-BMCS/DMDG New Perspectives\nin DMPK and Medicinal Chemistry Conference, held at the Burlington House in\nLondon.\n\nThe presentation features results from metabolite identification studies\nconducted using plasma samples obtained from healthy volunteers enrolled in\nthe recently completed Single Ascending Dose (SAD) clinical study of ART26.12.\nSince drug metabolism and pharmacokinetic properties are critical factors\ncontributing to successful clinical development, early characterization of\nART26.12's metabolite profile provides valuable insight that may help\nstreamline future development activities and reduce program risk.\n\nKey findings include:\n* Only three metabolites were detected from the plasma of healthy volunteers\nadministered a single 900 mg oral dose of ART26.12.\n* Total metabolite exposure represented approximately 7% of overall\ndrug-related exposure, indicating that the vast majority of circulating\ndrug-related material was the parent compound, ART26.12.\n* The primary metabolite detected, accounting for approximately 5% of total\ndrug-related exposure, was successfully identified and shown to have\nbiological activity comparable to ART26.12.\n* All three metabolites identified in humans were previously detected in the\nnonclinical species used in the ART26.12 toxicology program and are of no\nsafety concern.\n* Collectively, these findings suggest a low-risk metabolite profile, which\nmay simplify future development activities and further support advancement of\nART26.12 through clinical development.\n\"Understanding the metabolic fate of ART26.12 early in clinical development\nhas been an important objective for our team,\" said Myles Osborn, Lead\nMedicinal Chemist at Artelo. \"It was important for us to quantify and gain\nearly structural and biological knowledge of the metabolites, which we believe\nwill de-risk and significantly simplify future development of ART26.12.\"\n\n\"Up to 40% of drug development failures have historically been attributed to\nchallenges associated with pharmacokinetics and ADME (i.e. Absorption,\nDistribution, Metabolism and Excretion) properties,\" said Andrew Yates, Ph.D.,\nChief Scientific Officer of Artelo. \"These data further strengthen our\nconfidence in ART26.12, adding to the positive dose-proportional\npharmacokinetics, safety and tolerability observations we have already\nreported from our SAD study ART26.12-100. Importantly, the absence of\nhuman-specific metabolites and the low overall metabolite burden with ART26.12\nis expected to reduce future development complexity, timelines, and cost.\"\n\nIn summary, the ART26.12 metabolite profile characterized from healthy\nvolunteers is comprised of low plasma levels of only three metabolites\npreviously observed and qualified in its toxicology program. These results\nsuggest that these low level metabolites do not present a safety concern and,\ntogether with the remarkable safety profile observed in the SAD study, support\nthe continued development of ART26.12 for the treatment of pain.\n\nAbout Artelo Biosciences   \n\nArtelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated\nto the development and commercialization of proprietary therapeutics that\nmodulate lipid-signaling pathways, with a diversified pipeline addressing\nsignificant unmet needs in anorexia, cancer, anxiety, dermatologic conditions,\npain, and inflammation. Led by an experienced executive team collaborating\nwith world-class researchers and technology partners, Artelo applies rigorous\nscientific, regulatory, commercial, and treasury management practices,\nincluding digital assets, to maximize stakeholder value. More information is\navailable at www.artelobio.com and X: @ArteloBio.\n\nAbout ART26.12\n\nART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, is\nunder development as a novel, peripherally acting, non-opioid, non-steroidal\nanalgesic, initially for the treatment of chemotherapy-induced peripheral\nneuropathy (CIPN). Human studies with ART26.12 have demonstrated a favorable\nsafety profile with no serious adverse events, as well as predictable, linear\npharmacokinetics and dosing flexibility in both fed and fasted states. Fatty\nAcid Binding Proteins (FABPs) are a family of intracellular proteins that\nchaperone lipids important to normal cellular function. In addition to\nART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs\nhas shown therapeutic promise for the treatment of certain cancers,\nneuropathic and nociceptive pain, psoriasis, and anxiety disorders.\n\nForward-Looking Statements\n\nThis press release contains certain forward-looking statements within the\nmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the\nSecurities Exchange Act of 1934 and Private Securities Litigation Reform Act,\nas amended, including those relating to the Company’s product development,\nclinical and regulatory timelines, market opportunity, competitive position,\npossible or assumed future results of operations, business strategies,\npotential growth opportunities and other statements that are predictive in\nnature. These forward-looking statements are based on current expectations,\nestimates, forecasts and projections about the industry and markets in which\nwe operate and management’s current beliefs and assumptions. These\nstatements may be identified by the use of forward-looking expressions,\nincluding, but not limited to, “expect,” “anticipate,” “intend,”\n“plan,” “believe,” “estimate,” “potential,” “predict,”\n“project,” “should,” “would” and similar expressions and the\nnegatives of those terms. These statements relate to future events or our\nfinancial performance and involve known and unknown risks, uncertainties, and\nother factors which may cause actual results, performance or achievements to\nbe materially different from any future results, performance or achievements\nexpressed or implied by the forward-looking statements. Such factors include\nthose set forth in the Company’s filings with the Securities and Exchange\nCommission, including our ability to raise additional capital in the future.\nProspective investors are cautioned not to place undue reliance on such\nforward-looking statements, which speak only as of the date of this press\nrelease. The Company undertakes no obligation to publicly update any\nforward-looking statement, whether as a result of new information, future\nevents or otherwise, except to the extent required by applicable securities\nlaws.\n\nInvestor Relations Contact: \nCrescendo Communications, LLC \nTel: 212-671-1020 \nEmail: ARTL@crescendo-ir.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/460502d7-b0d3-43d8-a15a-5b2bb963bbbb)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-10T11:38:00.136476337Z","server_sent_at_ms":1781091480136},"received_at":"2026-06-10T11:38:00.189Z","source_url":null},"analysis":{"id":"49351","press_release_id":"59925","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Artelo Biosciences presented metabolite profiling data for its lead candidate ART26.12 at the RSC-BMCS/DMDG conference in London.\n\nThe data, derived from a recently completed Single Ascending Dose (SAD) study, showed only three metabolites with total exposure representing just 7% of overall drug-related exposure.\n\nThe absence of human-specific metabolites and the low metabolite burden are expected to reduce development complexity, timelines, and cost, supporting the program's advancement for pain treatment.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Scientific de-risking update for ART26.12; favorable metabolite profile supports continued development."},"keyFigures":{"drugName":"ART26.12","phaseOfTrial":"Phase 1","customDimensions":{"sad_dose_mg":900,"metabolite_exposure_pct":"7%","num_metabolites_detected":3,"primary_metabolite_exposure_pct":"5%"}},"quotedText":"These data further strengthen our confidence in ART26.12, adding to the positive dose-proportional pharmacokinetics, safety and tolerability observations we have already reported from our SAD study ART26.12-100.","namedEntities":{"people":[{"name":"Myles Osborn","role":"Lead Medicinal Chemist"},{"name":"Andrew Yates","role":"Chief Scientific Officer"}],"products":["ART26.12"],"companies":[{"name":"Artelo Biosciences, Inc.","ticker":"ARTL"},{"name":"Crescendo Communications, LLC","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Presentation of favorable metabolite data from a completed Phase 1 SAD study. This is a de-risking scientific update that supports continued development but does not represent a binary regulatory milestone or efficacy readout."},"tickerRelevance":{"others":[],"primary":"ARTL"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"scientific_update","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Artelo Biosciences presented metabolite profiling data for its lead candidate ART26.12 at the RSC-BMCS/DMDG conference in London.\n\nThe data, derived from a recently completed Single Ascending Dose (SAD) study, showed only three metabolites with total exposure representing just 7% of overall drug-related exposure.\n\nThe absence of human-specific metabolites and the low metabolite burden are expected to reduce development complexity, timelines, and cost, supporting the program's advancement for pain treatment.","key_figures":{"drugName":"ART26.12","phaseOfTrial":"Phase 1","customDimensions":{"sad_dose_mg":900,"metabolite_exposure_pct":"7%","num_metabolites_detected":3,"primary_metabolite_exposure_pct":"5%"}},"named_entities":{"people":[{"name":"Myles Osborn","role":"Lead Medicinal Chemist"},{"name":"Andrew Yates","role":"Chief Scientific Officer"}],"products":["ART26.12"],"companies":[{"name":"Artelo Biosciences, Inc.","ticker":"ARTL"},{"name":"Crescendo Communications, LLC","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-10T11:38:10.759Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"scientific_update","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":10557,"modelName":"george-droid-qwen-72b"}}